Low biologic aggressiveness in breast cancer in women using hormone replacement therapy

Journal of Clinical Oncology

Volumn 16, Issue 9, 1998, Pages 3115-3120

  Holli, Kaija ^a   Isola, Jorma ^b   Cuzick, Jack ^b  

^a TAMPERE UNIVERSITY HOSPITAL   (Finland)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

DNA; ESTROGEN; ESTROGEN RECEPTOR; PROGESTERONE; PROGESTERONE RECEPTOR;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER GRADING; CANCER SURVIVAL; CELL CYCLE S PHASE; CELL PROLIFERATION; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ACTIVITY; FEMALE; HORMONE SUBSTITUTION; HUMAN; MAJOR CLINICAL STUDY; MAMMOGRAPHY; ONCOGENE C ERB; PLOIDY; POSTMENOPAUSE; PRIORITY JOURNAL; PROGNOSIS; TUMOR VOLUME;

EID: 0031717805     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1998.16.9.3115     Document Type: Article

References (23)

1. Colditz G, Hankinson S, Hunter D, et al: The use of estrogen and progestin and the risk of breast cancer in postmenopausal women. N Engl J Med 332:1589-1593, 1995
2. Collaborative Group on Hormonal Factors in Breast Cancer: Breast cancer and hormone replacement therapy: Collaborative analysis of data from 51 epidemiological studies of 52705 women with breast cancer and 108411 women without breast cancer. Lancet 350:1047-1059, 1997
3. Yuen J, Persson I, Bergkvist L, et al: Hormone replacement therapy and breast cancer mortality in Swedish women: Results after adjustment for "healthy drug-user" effect. Cancer Causes Control 4:369-374, 1993
4. Hunt K, Vessey M, McPherson K: Mortality in a cohort of long-term users of hormone replacement therapy: An updated analysis. Br J Obstet Gynaecol 97:1080-1086, 1990
5. Henderson B, Paganini-Hill A, Ross R: Decreased mortality in users of estrogen replacement therapy. Arch Intern Med 151:75-78, 1991
6. Willis DB, Calle EE, Miracle-McMahill H, et al: Estrogen replacement therapy and risk of fatal breast cancer in a prospective cohort of postmenopausal women in the United States. Cancer Causes Control 7:449-457, 1996
7. Grodstein F, Stampfer M, Colditz C, et al: Postmenopausal hormone therapy and mortality. N Engl J Med 336:1769-1775, 1997
8. Bergkvist L, Adami HO, Persson I, et al: Prognosis after breast cancer diagnosis in women exposed to estrogen and estrogen-progestogen replacement therapy. Am J Epidemiol 130:221-228, 1989
9. Brinton L, Hoover R, Fraumeni J: Menopausal oestrogens and breast cancer risk: An expanded case-control study. Br J Cancer 54:825-832, 1986
10. Magnusson C, Holmberg L, Norden T, et al: Prognostic characteristics in breast cancers after hormone replacement therapy. Breast Cancer Res Treat 38:325-334, 1996
11. Collaborative Group on Hormonal Factors in Breast Cancer: Breast cancer and hormonal contraceptives: Collaborative re-analysis of individual data on 53297 women with breast cancer and 100239 women without breast cancer from 54 epidemiological studies. Lancet 347:1713-1727, 1996
12. Schairer C, Byrne C, Keyl P, et al: Menopausal estrogen and estrogen-progestin therapy and risk of breast cancer (United States). Cancer Causes Control 5:491-500, 1994
13. Squitieri R, Tartter PI, Ahmed S, et al: Carcinoma of the breast in postmenopausal hormone user and nonuser control groups. J Am Coll Surg 178:167-170, 1994
14. Bonnier P, Romain S, Giacalone P, et al: Clinical and biologic prognostic factors in breast cancer diagnosed during postmenopausal hormone replacement therapy. Obstet Gynecol 85:11-17, 1995
15. Harding C, Knox W, Faragher E, et al: Hormone replacement therapy and tumour grade in breast cancer: Prospective study in screening unit. BMJ 312:1646-1647, 1996
16. Salmon R, Remvikos Y, Ansquer Y, et al: HRT and breast cancer. Lancet 346:1702-1703, 1995
17. Bloom H, Richardson W: Histological grading and prognosis of breast cancer. Cancer 11:359-377, 1957
18. Helin H, Kallioniemi O-P, Isola J: Immunohistochemical determination of estrogen and progesterone receptors in human breast carcinoma. Correlation with histopathology and DNA flow cytometry. Cancer 63:1761-1767, 1989
19. Kallioniemi OP: Comparison of fresh and paraffin-embedded tissue as starting material for DNA flow cytometry and evaluation of intratumor heterogeneity. Cytometry 9:164-169, 1988
20. Cuzick J: A Wilcoxon-type test for trend. Stat Med 4:87-90, 1985
21. Helin H, Isola J, Helle M: Influence of endocrine status on immunocytochemical and biochemical estrogen and progesterone receptor assays in breast cancer patients. Breast Cancer Res Treat 12:67-73, 1988
22. Suhonen S: Vaihde-ja tasannevuosien uudistuva hormonihoito. Duodecim 110:1011-1018, 1994
23. Donegan WL: Tumor-related prognostic factors for breast cancer. CA Cancer J Clin 47:28-51, 1997